Semaglutide Improves Weight Loss in Type 1 Diabetes Patients
The study represents the first randomized clinical trial exploring semaglutide use in people with Type 1 diabetes.
Complete the form below to unlock access to ALL audio articles.
A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide — a medication typically prescribed to Type 2 diabetes patients — improved blood sugar levels and weight loss for adult Type 1 diabetes patients who use automated insulin delivery systems and have a body mass index of 30 or higher.
The results, published Monday in NEJM Evidence, represent the first randomized clinical trial exploring semaglutide use in people with Type 1 diabetes, for whom the drug is not currently FDA approved.
"We found that semaglutide was effective in improving time spent in the target blood sugar range and reduction in body weight compared to placebo group," said Viral Shah, MD, lead study author and IU School of Medicine professor of medicine.
Researchers in the 26-week, double-blind study found that 36% of the 36 patients taking semaglutide:
- Achieved target blood glucose levels of over 70% time spent in range of 70 to 180 mg/dl.
- Reduced time spent with low blood sugar (lower than 70 mg/dl) to less than 4%.
- Lost at least 5% of their body weight.
None of the 36 patients taking a placebo achieved all three of these milestones.
Those patients taking semaglutide lost an average of 20 pounds without any observed severe complications.
There were two severe hypoglycemia events in each group and no diabetic ketoacidosis was reported.
Semaglutide is part of a class of drugs known as glucagon-like peptide-1, or GLP-1, receptor agonists. Although introduced as a Type 2 diabetes medication, it has recently gained prominence as a weight-loss drug.
"We hope that our trial will encourage the industry to conduct a regulatory approval trial so that this drug could be available as an adjunct to insulin therapy to optimize Type 1 diabetes management," Shah said.
Reference: Shah Viral N., Akturk Halis K., Kruger Davida, et al. Semaglutide in adults with Type 1 diabetes and obesity. New Engl J Med Evid. 2025. doi: 10.1056/EVIDoa2500173
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
